Dysregulation of the immune response affects the outcome of critical COVID-19 patients

Area of Science:

• Immunology
• Critical Care Medicine
• Virology

Background:

• Critical coronavirus disease 2019 (COVID-19) carries a high mortality risk.
• Prognostic factors in critical COVID-19 patients remain incompletely understood.
• Varied patient outcomes in critical COVID-19 necessitate further investigation into underlying mechanisms.

Purpose of the Study:

• To investigate immune cell phenotypes and functions associated with prognosis in critical COVID-19.
• To identify immune markers that differentiate between good and poor outcomes in severe COVID-19.
• To explore the role of immune dysregulation in critical COVID-19 patient prognosis.

Main Methods:

• Comparative analysis of immune cell populations in critical COVID-19 patients.
• Peripheral blood samples collected at admission and exacerbation.
• Flow cytometry used to assess phenotypes and functions of immune cells (monocytes, macrophages, T cells, dendritic cells, neutrophils).

Main Results:

• On admission, good prognosis patients had higher monocytes, macrophages, specific CD4+ T cell subsets, and dendritic cells, with lower neutrophils compared to poor prognosis patients.
• At exacerbation, poor prognosis patients exhibited higher naive CD4+ T cells, Tregs, and Th2 cells, and lower CD4+ memory T cells.
• Significant differences in immune cell profiles were observed between good and poor prognosis groups at both time points.

Conclusions:

• Critical COVID-19 patients with poor prognoses demonstrate a less effective immune response.
• Immune dysregulation is a key factor influencing outcomes in severe COVID-19.
• Immune cell profiling may aid in predicting prognosis for critical COVID-19 patients.